AMSTERDAM, April 26, 2016 /PRNewswire/ -- Royal
Philips (NYSE: PHG; AEX: PHIA) today announced that any
hospital or healthcare facility with one of its indicated computed
tomography (CT) models can now become a lung cancer screening
center. Philips' suite of CT solutions has achieved 510(k)
clearance from the Food and Drug Administration (FDA) for low-dose
lung cancer screening (LCS). The suite includes 27 CT and PET/CT
models, as well as integrated software and services, which together
are the industry's most comprehensive lung cancer screening
solution.
Lung cancer is the leading cause of cancer death among both men
and women in the U.S.[1], and the source of one in four cancer
deaths[2]. Screenings are recommended by the Center for Medicare
& Medicaid Services (CMS) to help identify the disease earlier
in high risk populations when treatment can be more successful.
Early detection using this method has been shown to not only
improve prognosis and treatment, but decrease death rates up to 20
percent[3]. In addition, if diagnosed in stage one, patients can
have up to a 49 percent chance of surviving, compared to a
diagnosis at stage three where the survival rate is as low as 5
percent[4].
"Lung cancer is the number-one cancer killer in America, taking
more American lives than colon, breast and prostate cancer
combined, and early detection is key to fighting this terrible
disease," said Brady J. McKee,
radiologist at Lahey Hospital and Medical Center, a pioneer in the
early detection of lung cancer, featuring the largest clinical lung
cancer screening program in the country. "The work Philips has done
to improve a provider's screening capability not only benefits
individual patients, but hospitals at each step of their Lung
Cancer Screening program implementation and execution, which is
often a very complicated process that includes community outreach,
physician education, patient and data management, and
reporting."
Philips' low-dose CT solutions now give healthcare organizations
of varying clinical and economic needs — from community hospitals
to multi-facility health systems — the ability to build robust lung
cancer screening programs. Through its integrated radiology
solutions and services, Philips can work with healthcare executives
to better assess availability of existing scanners and to establish
an enterprise-wide lung cancer program that will deliver advanced
patient care and access.
"Our robust portfolio of CT solutions offers our customers in
the United States a turnkey
approach to lung cancer screening," said Rob Cascella, CEO, Diagnostic Imaging, Philips.
"This is a complementary offering to utilize existing systems to
bring low-dose CT screening to healthcare facilities of all sizes
who want to drive earlier detection for patients at high risk for
lung cancer."
Philips lung cancer screening solutions also provide several
benefits for patients and referring physicians, including:
- Personalized management of radiation dose – Offering one
of the most accelerated screening approaches in the industry, the
27 models of Philips CT and PET/CT solutions qualified with the
indications for use to perform CT lung cancer screening also
utilize active dose management tools.
- Greater insights throughout the process – Referring
physicians are better able to manage the process from end-to-end
through "control center" software tools that enable digital access
to patient tracking data that proves insight into scheduling,
results and follow-up activities.
- Advanced image data sharing and analytics – Through its
IntelliSpace Portal, Philips offers one of the most comprehensive
solutions for detection, diagnostics and therapy follow up. To
address the increasing interest in pulmonary care, the latest
version, IntelliSpace Portal 8.0, now includes the new CT Lung
Nodule Assessment (LNA) application designed for a more efficient
and longitudinal workflow to provide additional clinical decision
support.
The Philips commitment to innovative radiology solutions
includes improving services and continuing to engage with radiology
customers, delivering integrated software, solutions and services
that resonate with their specific needs. Philips provides radiology
practices with the critical insights needed to transform care,
enabling practices to be more efficient and effective, while
shaping positive clinical, financial and operational environments.
This commitment helps to improve people's health and enable better
care across the entire health continuum.
For further information, please contact:
Adrienne Smith
Philips Diagnostic Imaging
Tel: +1 781-277-1170
Email: Adrienne.Smith@philips.com
Kathy O'Reilly
Philips Group Communications
Tel: +1 978 – 221 – 8919
Email: Kathy.oreilly@philips.com
@kathyoreilly
About Royal Philips
Royal Philips (NYSE: PHG, AEX:
PHIA) is a leading health technology company focused on improving
people's health and enabling better outcomes across
the health continuum from healthy living and prevention, to
diagnosis, treatment and home care. Philips leverages advanced
technology and deep clinical and consumer insights to
deliver integrated solutions. The company is a leader in
diagnostic imaging, image-guided therapy, patient
monitoring and health informatics, as well as
in consumer health and home care. Philips'
wholly owned subsidiary Philips Lighting is the
global leader in lighting products, systems and
services. Headquartered in the
Netherlands, Philips posted 2015 sales of EUR 24.2 billion and employs approximately
104,000 employees with sales and services in more than 100
countries. News about Philips can be found at
www.philips.com/newscenter.
[1] Centers for Disease Control and Prevention. National
Center for Health Statistics. CDC Wonder On-line
Database, compiled from Compressed Mortality File 1999-2012
Series 20 No. 2R, 2014.
[2] American Cancer Society, Key Statistics for Lung
Cancer, 2016
[3] N Engl J Med, 2011; 365:395-409. National Lung Screening
Trial research team. Reduced lung cancer mortality with low dose
computed tomographic screening.
[4] J National Cancer Institute, 100, no.9 (2008): 630-641;
Oncology Roundtable interviews and analysis.
Logo -
http://photos.prnewswire.com/prnh/20140122/NE50581LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/philips-receives-fda-510k-clearance-of-ct-imaging-solutions-for-lung-cancer-screening-to-help-hospitals-of-all-sizes-drive-earlier-detection-and-improve-patient-care-decisions-300257063.html
SOURCE Royal Philips